Rheumatoid Arthritis Awareness Day: Gaps Remain Despite Therapeutic Advances

Today, February 2nd, is Rheumatoid Arthritis Awareness Day. Rheumatoid arthritis (RA) affects an estimated 1% of adults worldwide and remains a leading cause of chronic pain, disability, and reduced quality of life despite substantial therapeutic progress over the past 2 decades.¹ RA Awareness Day serves as an opportunity to underscore both the gains achieved through earlier diagnosis and expanded treatment options, as well as the ongoing challenges that continue to affect patients and clinicians.

The introduction of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), followed by biologic and targeted synthetic DMARDs, has transformed outcomes for many patients, making sustained remission or low disease activity an achievable goal.² Current management strategies emphasize early intervention and a treat-to-target approach, supported by international guidelines from the American College of Rheumatology (ACR) and the European Alliance of Associations for Rheumatology (EULAR).²,³ However, population-level data show that a substantial proportion of patients do not achieve durable remission, and many continue to experience pain, fatigue, and functional limitations even when inflammatory markers are controlled.⁴

At the same time, the expanding therapeutic armamentarium—now encompassing multiple mechanisms of action—has introduced new complexity into clinical decision-making. Biomarkers that reliably predict treatment response or guide individualized therapy selection remain an area of active investigation, but none are currently validated for routine clinical use.

In recognition of RA Awareness Day, we spoke to Arthur M. Mandelin, MD, PhD, Associate Professor of Medicine (Rheumatology) at Northwestern University - The Feinberg School of Medicine, and Daniel K. White, MS, ScD, Associate Professor in the Department of Physical Therapy at the University of Delaware, about what they view as the most pressing unmet needs in the field today. They emphasized that while the abundance of effective therapies represents major progress, the absence of tools to match the right therapy to the right patient often leaves clinicians reliant on trial-and-error prescribing.

The conversation also highlighted gaps beyond pharmacologic control of inflammation, including persistent pain, weakness, and functional impairment that may not fully respond to medication alone. Both White and Mandelin stressed the importance of integrating nonpharmacologic strategies—such as physical therapy, exercise, and lifestyle interventions—into comprehensive RA care, while noting the relative lack of large, well-funded studies in these areas. Together, their perspectives underscore that advancing RA care will require not only new drugs, but also better personalization of therapy and broader approaches to long-term disease management.

References

1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi: 0.1016/S0140-6736(16)30173-8

2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123.
   doi: 10.1002/art.41752

3. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological DMARDs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.
   doi: 10.1136/annrheumdis-2022-222770

4. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36(5):685-695.
   doi: 10.1007/s00296-015-3415-x